Impact of Ticagrelor in Patients With Prior MI and MVD for Reducing Cardiovascular Events

J Am Coll Cardiol. 2018 Feb 6;71(5):497-498. doi: 10.1016/j.jacc.2017.11.049.

Authors

Michael S Lee¹, Michael T Tanoue²

Affiliations

¹ Division of Cardiology, Ronald Regan UCLA Medical Center, University of California-Los Angeles, Los Angeles, California. Electronic address: MSLee@mednet.ucla.edu.
² Division of Cardiology, Ronald Regan UCLA Medical Center, University of California-Los Angeles, Los Angeles, California.

PMID: 29406854
DOI: 10.1016/j.jacc.2017.11.049

No abstract available

Keywords: P2Y12; acute coronary syndrome; dual antiplatelet therapy; ticagrelor.

Publication types

Editorial
Comment

MeSH terms

Coronary Artery Disease*
Humans
Purinergic P2Y Receptor Antagonists
Secondary Prevention
Ticagrelor*

Substances

Purinergic P2Y Receptor Antagonists
Ticagrelor